Structural members for prosthetic mitral valves

Information

  • Patent Grant
  • 11617645
  • Patent Number
    11,617,645
  • Date Filed
    Wednesday, July 17, 2019
    4 years ago
  • Date Issued
    Tuesday, April 4, 2023
    a year ago
Abstract
A self-expanding wire frame for a pre-configured compressible transcatheter prosthetic cardiovascular valve, a combined inner frame/outer frame support structure for a prosthetic valve, and methods for deploying such a valve for treatment of a patient in need thereof, are disclosed.
Description
BACKGROUND
Field of Invention

An improved transcatheter prosthetic heart valve includes structural members, such as in the form of wire frames, which provide support for the valve and aid in reducing or preventing leakage.


Background

Valvular heart disease and specifically aortic and mitral valve disease is a significant health issue in the US. Annually approximately 90,000 valve replacements are conducted in the US. Traditional valve replacement surgery, the orthotopic replacement of a heart valve, is an “open heart” surgical procedure. Briefly, the procedure necessitates a surgical opening of the thorax, initiation of extra-corporeal circulation with a heart-lung machine, stopping and opening the heart, excision and replacement of the diseased valve, and re-starting of the heart. While valve replacement surgery typically carries a 1-4% mortality risk in otherwise healthy persons, a significantly higher morbidity is associated to the procedure, largely due to the necessity for extra-corporeal circulation. Further, open heart surgery is often poorly tolerated in elderly patients.


Thus if the extra-corporeal component of the procedure could be eliminated, morbidities and cost of valve replacement therapies would be significantly reduced.


While replacement of the aortic valve in a transcatheter manner is the subject of intense investigation, lesser attention has been focused on the mitral valve. This is in part reflective of the greater level of complexity associated to the native mitral valve apparatus and thus a greater level of difficulty with regards to inserting and anchoring the replacement prosthesis.


Various problems exist in this field, including problems of insufficient articulation and sealing of the valve within the native annulus, pulmonary edema due to poor atrial drainage, perivalvular leaking around the installed prosthetic valve, lack of a good fit for the prosthetic valve within the native mitral annulus, atrial tissue erosion, excess wear on the valve structures, interference with the aorta at the posterior side of the mitral annulus, and lack of customization, to name a few. Accordingly, there is still a need for an improved prosthetic mitral valve.


SUMMARY

Apparatus, systems, and methods include a self-expanding wire frames for a prosthetic cardiovascular valve. The prosthetic cardiovascular valve includes a cylindrical framework defining a lumen. The cylindrical framework includes multiple generally diamond-shaped members. Each diamond-shaped member defines multiple lateral vertices and multiple longitudinal vertices. Each diamond-shaped member is coupled to one or more other diamond-shaped members. Each coupling can be at or about each of the lateral vertices of the diamond-shaped member.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an exploded view of a prosthetic cardiovascular valve according to an embodiment.



FIG. 2 is an oblique projection of a three-diamond self-expanding wire frame as a cylindrical frame defining a lumen according to an embodiment.



FIG. 3 is a perspective side view of a three-diamond self-expanding wire frame as a cylindrical frame defining a lumen according to another embodiment.



FIG. 4 is an opened and flattened view of a three-diamond cylindrical frame showing the detail of wire rods, multiple spanning rods, and vertices, according to another embodiment.



FIG. 5 is an opened and flattened view of an open-V cylindrical frame showing the detail of wire rods, and vertices, according to another embodiment.



FIG. 6 is an opened and flattened view of a three-diamond cylindrical frame showing the detail of wire rods, spanning rods, and vertices, according to another embodiment.



FIG. 7 is an oblique projection of a four-diamond self-expanding wire frame as a cylindrical frame defining a lumen, according to another embodiment.



FIG. 8 is an opened and flattened view of a four-diamond cylindrical frame showing the detail of wire rods, multiple spanning rods, and vertices, according to another embodiment.



FIG. 9 is an opened and flattened view of an open-V cylindrical frame showing the detail of wire rods, and vertices, according to another embodiment.



FIG. 10 is an opened and flattened view of a four-diamond cylindrical frame showing the detail of wire rods, spanning rods, and vertices, according to another embodiment.



FIG. 11 is an oblique projection view of a three-square cylindrical frame showing the detail of wire rods, multiple spanning rods, and vertices, according to another embodiment.



FIG. 12 is an opened and flattened view of the frame of FIG. 11.



FIG. 13 is an exploded view of a prosthetic cardiovascular valve according to another embodiment.



FIGS. 14A-14C show initial, partially expanded, and fully expanded states of an outer frame according to an embodiment.



FIG. 15 is an exploded view of a prosthetic cardiovascular valve according to another embodiment.



FIG. 16 is an opened and flattened view of an unexpanded inner wireframe structure, according to an embodiment.



FIGS. 17 and 18 are side and bottom views, respectively, of the inner wireframe structure of FIG. 16 in an expanded configuration.



FIG. 19 is an opened and flattened view of an unexpanded outer frame according to an embodiment.



FIGS. 20 and 21 are side and top views, respectively, of the outer frame of FIG. 19 in an expanded configuration.



FIGS. 22-24 are side, front, and top views of an assembly of the inner wireframe structure of FIGS. 16-18 and the outer frame of FIGS. 19-21, forming a support structure for a prosthetic valve, according to an embodiment.





DETAILED DESCRIPTION


FIG. 1 is an exploded view of one embodiment of a pre-configured compressible transcatheter prosthetic cardiovascular valve 10. In this embodiment, valve 10 includes an inner structure or assembly 12, and an outer structure or assembly 14. Valve 10 may be coupled to a tether 160, and a tether anchor 154.


Inner assembly 12 includes a self-expanding frame 100, an outer cylindrical wrap 152 disposed about the inner wire frame (to acts as a cover to prevent valvular leakage) and a leaflet structure 136 (comprised of articulating leaflets 138 that define a valve function). The leaflet structure 136 may be sewn to the inner wireframe 100. The wireframe 100 also has (tether) attachment apertures 111 to which the tether 160 can be attached. Tether 160 is connected to tether anchor 154, which in this embodiment is implemented as an epicardial securing pad.


Outer assembly 14 includes an outer stent or frame 144, an outer cover 150, and a cuff covering 148. In this embodiment, outer frame 144 has a flared, articulating collar or cuff 146 over which the cuff covering 148 is disposed. Cuff 146 has a D-shaped section 162 to accommodate and solve left ventricular outflow tract (LVOT) obstruction issues.


Cuff 146 may be configured a substantially flat plate that projects beyond the diameter of the tubular body of outer frame 144 to form a rim or border. The terms flared end, cuff, flange, collar, bonnet, apron, or skirting used interchangeable herein. When the tubular body of frame 144 is pulled through the aperture of a mitral valve aperture, the mitral annulus, such as by tether loops, in the direction of the left ventricle, the cuff acts as a collar to stop the frame from traveling any further through the mitral valve aperture. The entire prosthetic valve is held by longitudinal forces between the cuff, which is seated in the left atrium and mitral annulus, and the ventricular tethers attached to the left ventricle.


Cuff 146 may be formed from a stiff, flexible shape-memory material such as the nickel-titanium alloy material Nitinol® formed as wire, and covered by cuff covering 148, which may be formed of stabilized tissue or other suitable biocompatible or synthetic material. In one embodiment, the cuff is constructed from independent articulating radial tines or posts of wire extending axially around the circumference of the bend or seam where cuff 146 transitions to the tubular body of frame 144 (in an integral flared end or cuff) or where cuff 146 is attached to the frame body (in an implementation in which they are separate, but joined components).


With cuff cover 148 in place articulating radial tines or posts of wire provide the cuff the ability to move up and down, to articulate, along the longitudinal axis that runs through the center of frame 144. In other words, the individual articulating radial tines or posts of wire can independently move up and down, and can spring back to their original position due to the relative stiffness of the wire. The tissue or material that covers the cuff wire has a certain modulus of elasticity such that, when attached to the wire of the cuff, is able to allow the wire spindles to move. This flexibility gives the cuff, upon being deployed within a patient's heart, the ability to conform to the anatomical shape necessary for a particular application. In the example of a prosthetic mitral valve, the cuff is able to conform to the irregularities of the left atrium and shape of the mitral annulus, and to provide a tight seal against the atrial tissue adjacent the mitral annulus and the tissue within the mitral annulus. As stated previously, this feature provides a degree of flexibility in sizing the mitral valve and prevents blood from leaking around the implanted prosthetic heart valve.


An additional aspect of the cuff dimension and shape is that, when fully seated and secured, the edge of the cuff preferably should not be oriented laterally into the atrial wall, in which orientation it might produce a penetrating or cutting action on the atrial wall.


In some embodiments, the wire spindles of the cuff are substantially uniform in shape and size. In some embodiments, each loop or spindle may be of varying shapes and sizes. In this example, it is contemplated that the articulating radial tines or posts of wire may form a pattern of alternating large and small articulating radial tines or posts of wire, depending on where the valve is being deployed. In the case of a prosthetic mitral valve, pre-operative imaging may allow for customizing the structure of the cuff depending on a particular patient's anatomical geometry in the vicinity of the mitral annulus.


The cuff is constructed so as to provide sufficient structural integrity to withstand the intracardiac forces without collapsing.


Inner frame 100 and outer frame or frame 144, including cuff 146, are preferably formed to be deformed (compressed and/or expanded) and, when released, return to their original (undeformed) shapes. To achieve this, the components are preferably formed of materials, such as metals or plastics, that have shape memory properties. With regards to metals, Nitinol® has been found to be especially useful since it can be processed to be austenitic, martensitic or super elastic. Martensitic and super elastic alloys can be processed to demonstrate the required compression features. Thus, inner frame 100 and outer frame or frame 144, including cuff 145, are preferably constructed of Nitinol®, and are capable of maintaining their functions while under longitudinal forces that might cause a structural deformation or valve displacement. Other shape memory alloys, such as Cu—Zn—Al—Ni alloys, and Cu—Al—Ni alloys, may be used.


Inner frame 100 and outer frame or frame 144, including cuff 146, are preferably formed from a laser cut, thin-walled tube of Nitinol® The laser cuts form regular cutouts in the thin Nitinol® tube. Secondarily the tube is placed on a mold of the desired shape, heated to the martensitic temperature and quenched. The treatment of the frame in this manner will form a flared end or cuff that has shape memory properties and will readily revert to the memory shape at the calibrated temperature.


Alternatively, these components may be constructed from braided wire


The cuff provides several functions. The first function is to inhibit perivalvular leakage and regurgitation of blood around the prosthesis. By flexing and sealing across the irregular contours of the annulus and atrium, leakage is minimized or prevented.


The second function of the cuff is to provide an adjustable and/or compliant bioprosthetic valve. The heart and its structures undergo complex conformational changes during the cardiac cycle. For example, the mitral valve annulus has a complex geometric shape known as a hyperbolic paraboloid that is shaped like a saddle, with the horn being anterior, the seat back being posterior, and the left and right valleys located medially and laterally. Beyond this complexity, the area of the mitral annulus changes over the course of the cardiac cycle. Further, the geometry of the tricuspid valve and tricuspid annulus continues to be a topic of research, posing its own particular problems. Accordingly, compliance is a very important but unfortunately often overlooked requirement of cardiac devices. Compliance here refers to the ability of the valve to change conformation with the native annulus in order to maintain structural position and integrity throughout the cardiac cycle. Compliance with the motion of the heart is a particularly useful feature, especially the ability to provide localized compliance where the underlying surfaces are acting differently from the adjacent surfaces. This ability to vary throughout the cardiac cycle allows the valve to remain seated and properly deployed in a manner not heretofore provided.


Additionally, compliance may be achieved through the use of the tethers where the tethers are preferably made from an elastic material. Tether-based compliance may be used alone, or in combination with the cuff-based compliance.


The third function of the cuff is to enable the valve, during implantation surgery, to conform to the irregular surfaces of the atrium. This function can be enhanced by the use of independent tethers, allowing for side-to-side fitting of the valve within the annulus. For example, where three tethers are used, they can be spaced circumferentially about 120 degrees relative to each other, which allows the surgeon to observe whether or where perivalvular leaking might be occurring and to pull on one side or the other to create localized pressure and reduce or eliminate the leakage.


The fourth function of the cuff is to counter the forces that act to displace the prosthesis toward/into the ventricle (i.e. atrial pressure and flow-generated shear stress) during ventricular filling.


The heart is known to generate an average left atrial pressure between about 8 and 30 mm Hg (about 0.15 to 0.6 psi). This left atrial filling pressure is the expected approximate pressure that would be exerted in the direction of the left ventricle when the prosthesis is open against the outer face of the flared end or cuff as an anchoring force holding the flared end or cuff against the atrial tissue that is adjacent the mitral valve. Cuff 146 counteracts this longitudinal pressure against the prosthesis in the direction of the left ventricle to keep the valve from being displaced or slipping into the ventricle. In contrast, left ventricular systolic pressure, normally about 120 mm Hg, exerts a force on the closed prosthesis in the direction of the left atrium. The tethers counteract this force and are used to maintain the valve position and withstand the ventricular force during ventricular contraction or systole. Accordingly, cuff 146 has sufficient structural integrity to provide the necessary tension against the tethers without being dislodged and pulled into the left ventricle. After a period of time, changes in the geometry of the heart and/or fibrous adhesion between prosthesis and surrounding cardiac tissues may assist or replace the function of the ventricular tethers in resisting longitudinal forces on the valve prosthesis during ventricular contraction.


Additional features of the cuff include that it functions to strengthen the leaflet assembly/frame complex by providing additional structure. Further, during deployment, the cuff functions to guide the entire structure, the prosthetic valve, into place at the mitral annulus during deployment and to keep the valve in place once it is deployed. Another important function is to reduce pulmonary edema by improving atrial drainage.


The valve leaflets are held by, or within, a leaflet assembly. In some embodiments, the leaflet assembly comprises a leaflet wire support structure to which the leaflets are attached and the entire leaflet assembly is housed within the frame body. In this embodiment, the assembly is constructed of wire and stabilized tissue to form a suitable platform for attaching the leaflets. In this aspect, the wire and stabilized tissue allow for the leaflet structure to be compressed when the prosthetic valve is compressed within the deployment catheter, and to spring open into the proper functional shape when the prosthetic valve is opened during deployment. In this embodiment, the leaflet assembly may optionally be attached to and housed within a separate cylindrical liner made of stabilized tissue or material, and the liner is then attached to line the interior of the frame body.


In this embodiment, the leaflet wire support structure is constructed to have a collapsible/expandable geometry. In some embodiments, the structure is a single piece of wire. The wireform is, in one embodiment, constructed from a shape memory alloy such as Nitinol®. The structure may optionally be made of a plurality of wires, including between 2 to 10 wires. Further, the geometry of the wire form is without limitation, and may optionally be a series of parabolic inverted collapsible arches to mimic the saddle-like shape of the native annulus when the leaflets are attached. Alternatively, it may optionally be constructed as collapsible concentric rings, or other similar geometric forms, each of which is able to collapse or compress, then expand back to its functional shape. In some embodiments, there may be 2, 3 or 4 arches. In another embodiment, closed circular or ellipsoid structure designs are contemplated. In another embodiment, the wire form may be an umbrella-type structure, or other similar unfold-and-lock-open designs. In some embodiments utilizes super elastic Nitinol® wire approximately 0.015″ in diameter. In this embodiment, the wire is wound around a shaping fixture in such a manner that 2-3 commissural posts are formed. The fixture containing the wrapped wire is placed in a muffle furnace at a pre-determined temperature to set the shape of the wire form and to impart its super elastic properties. Secondarily, the loose ends of the wireform are joined with a stainless steel or Nitinol® tube and crimped to form a continuous shape. In some embodiments, the commissural posts of the wireform are adjoined at their tips by a circular connecting ring, or halo, whose purpose is to minimize inward deflection of the post(s).


In some embodiments, the leaflet assembly is constructed solely of stabilized tissue or other suitable material without a separate wire support structure. The leaflet assembly in this embodiment is also disposed within the lumen of the frame and is attached to the frame to provide a sealed joint between the leaflet assembly and the inner wall of the frame. By definition, it is contemplated within the scope of the invention that any structure made from stabilized tissue and/or wire(s) related to supporting the leaflets within the frame constitute a leaflet assembly. In this embodiment, stabilized tissue or suitable material may also optionally be used as a liner for the inner wall of the frame and is considered part of the leaflet assembly.


Liner tissue or biocompatible material may be processed to have the same or different mechanical qualities, such as thickness, durability, etc., from the leaflet tissue.


Multiple types of tissue and biocompatible material may be used to cover the cuff, to form the valve leaflets, to form a wireless leaflet assembly, and/or to line both the inner and/or outer lateral walls of outer frame 144. As stated previously, the leaflet component may be constructed solely from stabilized tissue, without using wire, to create a leaflet assembly and valve leaflets. In this aspect, the tissue-only leaflet component may be attached to the frame with or without the use of the wire form. In some embodiments, there can be anywhere from 1, 2, 3 or 4 leaflets, or valve cusps.


The tissue may be used to cover the inside of the frame body, the outside of the frame body, and the top and/or bottom side of the cuff wire form, or any combination thereof.


In some embodiments, the tissue used herein is optionally a biological tissue and may be a chemically stabilized valve of an animal, such as a pig. In some embodiments, the biological tissue is used to make leaflets that are sewn or attached to a metal frame. This tissue is chemically stabilized pericardial tissue of an animal, such as a cow (bovine pericardium) or sheep (ovine pericardium) or pig (porcine pericardium) or horse (equine pericardium).


Preferably, the tissue is bovine pericardial tissue. Examples of suitable tissue include that used in the products Duraguard®, Peri-Guard®, and Vascu-Guard®, all products currently used in surgical procedures, and which are marketed as being harvested generally from cattle less than 30 months old.


In some embodiments, the valve leaflets may optionally be made from a synthetic material such as polyurethane or polytetrafluoroethylene. Where a thin, durable synthetic material is contemplated, e.g. for covering the flared end or cuff, synthetic polymer materials such expanded polytetrafluoroethylene or polyester may optionally be used. Other suitable materials may optionally include thermoplastic polycarbonate urethane, polyether urethane, segmented polyether urethane, silicone polyether urethane, silicone-polycarbonate urethane, and ultra-high molecular weight polyethylene. Additional biocompatible polymers may optionally include polyolefins, elastomers, polyethylene-glycols, polyethersulphones, polysulphones, polyvinylpyrrolidones, polyvinylchlorides, other fluoropolymers, silicone polyesters, siloxane polymers and/or oligomers, and/or polylactones, and block co-polymers using the same.


In another embodiment, the valve leaflets may optionally have a surface that has been treated with (or reacted with) an anti-coagulant, such as, without limitation, immobilized heparin. Such currently available heparinized polymers are known and available to a person of ordinary skill in the art.


Alternatively, the valve leaflets may optionally be made from pericardial tissue or small intestine submucosal tissue.


In another embodiment, the prosthetic valve is sized and configured for use in areas other than the mitral annulus, including, without limitation, the tricuspid valve between the right atrium and right ventricle. Alternative embodiments may optionally include variations to the flared end or cuff structure to accommodate deployment to the pulmonary valve between the right ventricle and pulmonary artery, and the aortic valve between the left ventricle and the aorta. In one embodiment, the prosthetic valve is optionally used as a venous backflow valve for the venous system, including without limitation the vena cava, femoral, subclavian, pulmonary, hepatic, renal and cardiac. In this aspect, the flared end or cuff feature is utilized to provide additional protection against leaking.


As shown in FIG. 1, tether 160 may be attached to valve 10. Tether 160 (which may include multiple tethers) may extend to one or more tissue anchor locations within the heart. In some embodiments, the tether(s) extends downward through the left ventricle, exiting the left ventricle at the apex of the heart to be fastened on the epicardial surface outside of the heart. Similar anchoring is contemplated herein as it regards the tricuspid, or other valve structure requiring a prosthetic. There may be from 1 to 8, or more, tethers.


In some embodiments, the tether(s) may optionally be attached to the cuff to provide additional control over position, adjustment, and compliance. In some embodiments, one or more tethers are optionally attached to the cuff, in addition to, or optionally, in place of, the tethers attached to the outer frame 144. By attaching to the cuff and/or the frame, an even higher degree of control over positioning, adjustment, and compliance is provided to the operator during deployment.


During deployment, the operator is able to adjust or customize the tethers to the correct length for a particular patient's anatomy. The tether(s) also allows the operator to tighten the cuff onto the tissue around the valvular annulus by pulling the tether(s), which creates a leak-free seal.


In some embodiments, the tether(s) is optionally anchored to other tissue location(s) depending on the particular application of valve 10. In the case of a mitral valve, or the tricuspid valve, one or more tethers are optionally anchored to one or both papillary muscles, septum, and/or ventricular wall.


In some embodiments, the ventricular end of outer frame 144, or of inner frame 100, comes to 2-5 points onto which anchoring sutures or tether are affixed. The tethers will traverse the ventricle and ultimately be anchored to the epicardial surface of the heart approximately at the level of the apex. The tethers when installed under slight tension will serve to hold the valve in place, i.e. inhibit perivalvular leakage during systole.


The tethers, in conjunction with the cuff, provide greater compliance for the valve. The tethers may be made from surgical-grade materials such as biocompatible polymer suture material. Non-limiting examples of such material include ultra high-molecular weight polyethylene (UHMWPE), 2-0 exPFTE (polytetrafluoroethylene) or 2-0 polypropylene. In one embodiment the tethers are inelastic. One or more of the tethers may optionally be elastic to provide an even further degree of compliance of the valve during the cardiac cycle. Upon being drawn to and through the apex of the heart, the tethers may be fastened by a suitable mechanism such as tying off to a pledget or similar adjustable button-type anchoring device to inhibit retraction of the tether back into the ventricle. It is also contemplated that the tethers might be bioresorbable/bioabsorbable and thereby provide temporary fixation until other types of fixation take hold such a biological fibrous adhesion between the tissues and prosthesis and/or radial compression from a reduction in the degree of heart chamber dilation.


Valve 10 may optionally be deployed with a combination of installation tethers and permanent tethers, attached to outer frame 144, and/or cuff 146, and/or inner frame 100, the installation tethers being removed after the valve is successfully deployed. It is also contemplated that combinations of inelastic and elastic tethers may optionally be used for deployment and to provide structural and positional compliance of the valve during the cardiac cycle.


Valve 10 may be deployed as a prosthetic mitral valve using catheter delivery techniques. The entire valve 10 is compressed within a narrow catheter and delivered to the annular region of the native valve, preferably the left atrium, with a pre-attached tether apparatus. There, the valve 10 is pushed out of the catheter where it springs open into its pre-formed functional shape without the need for manual expansion using an inner balloon catheter. When the valve 10 is pulled into place, the outer frame 144 is seated in the native mitral annulus, leaving the cuff 146 to engage the atrial floor and prevent pull-through (where the valve is pulled into the ventricle). The native leaflets are not cut-away as has been taught in prior prosthetic efforts, but are used to provide a tensioning and sealing function around the outer frame 144. The valve 10 is preferably deployed asymmetrically to address LVOT problems, unlike non-accommodating prosthetic valves that push against the A2 anterior segment of the mitral valve and close blood flow through the aorta, which anatomically sits immediately behind the A2 segment of the mitral annulus. Thus, D-shaped section 162 is preferably deployed immediately adjacent/contacting the A2 segment since the flattened D-shaped section 162 is structurally smaller and has a more vertical profile (closer to paralleling the longitudinal axis of the outer frame) and thereby exerts less pressure on the A2 segment. Once valve 10 is properly seated, tether 160 may be extended out through the apical region of the left ventricle and secured using an epicardial pad 154 or similar suture-locking attachment mechanism.


Valve 10 is, in one embodiment, apically delivered through the apex of the left ventricle of the heart using a catheter system. In one aspect of the apical delivery, the catheter system accesses the heart and pericardial space by intercostal delivery. In another delivery approach, the catheter system delivers valve 10 using either an antegrade or retrograde delivery approach using a flexible catheter system, and without requiring the rigid tube system commonly used. In another embodiment, the catheter system accesses the heart via a trans-septal approach.


In some embodiments, the frame body extends into the ventricle about to the edge of the open mitral valve leaflets (approximately 25% of the distance between the annulus and the ventricular apex). The open native leaflets lay against the outside frame wall and parallel to the long axis of the frame (i.e. the frame holds the native mitral valve open).


In some embodiments, the diameter should approximately match the diameter of the mitral annulus. Optionally, the valve may be positioned to sit in the mitral annulus at a slight angle directed away from the aortic valve such that it is not obstructing flow through the aortic valve. Optionally, the outflow portion (bottom) of the frame should not be too close to the lateral wall of the ventricle or papillary muscle as this position may interfere with flow through the prosthesis. As these options relate to the tricuspid, the position of the tricuspid valve may be very similar to that of the mitral valve.


In one embodiment, to control the potential tearing of tissue at the apical entry point of the delivery system, a circular, semi-circular, or multi-part pledget may be employed. The pledget may be constructed from a semi-rigid material such as PTFE felt. Prior to puncturing of the apex by the delivery system, the felt is firmly attached to the heart such that the apex is centrally located. Secondarily, the delivery system is introduced through the central area, or orifice as it may be, of the pledget. Positioned and attached in this manner, the pledget acts to control any potential tearing at the apex.


In another embodiment the valve can be seated within the valvular annulus through the use of tines or barbs. These may be used in conjunction with, or in place of one or more tethers. The tines or barbs are located to provide attachment to adjacent tissue. In some embodiments, the tines are optionally circumferentially located around the bend/transition area between frame body 144 and the cuff 146. Such tines are forced into the annular tissue by mechanical means such as using a balloon catheter. In one non-limiting embodiment, the tines may optionally be semi-circular hooks that upon expansion of the frame body, pierce, rotate into, and hold annular tissue securely.


One embodiment of an inner frame 100 is shown in side view in FIG. 2. Frame 100 includes a cylindrical framework 102 defining a lumen 104, and including three generally diamond-shaped members 106, 108, 110. Each diamond-shaped member is directly connected to, or has at least one connecting member 120 connecting to, each of the other two diamond-shaped members. Spanning members 122 cross the open span of the diamond-shaped members and provide a strengthening structural enhancement, another sewing anchor location for the other components of inner assembly 12, or both.


Another embodiment of inner frame 100 is shown in side view in FIG. 3. This embodiment includes optional valve sewing rings 105 and tether attachment structures 111. Each valve sewing ring 105 provides an aperture for sewing the leaflet tissue structures to the wire framework 100.


Another embodiment of inner frame 100 is shown in an opened and flattened view in FIG. 4. This view is intended primarily for illustrative purposes of the wireframe structure, since the manufacture of the cylindrical framework will generally be made from a laser-cut piece of Nitinol® tubing that is expanded to form a larger cylindrical structure, and the wireframe structure will generally not be manufactured from a rolled-up welded metal lattice. FIG. 4 shows each diamond-shaped member defining two lateral vertices 112 and 114 and two longitudinal vertices 116 and 118. Each diamond-shaped member is directly connected to, or has at least one connecting member 120 connecting to, each of the other two diamond-shaped members. The connecting members defined in this embodiment as joined legs 126, 128 connected at a V-shaped connecting vertex 124. FIG. 4 also shows spanning members 122 crossing the open span of the diamond-shaped members and providing a strengthening structural enhancement, another sewing anchor location, or both. FIG. 4 shows point A and point B, which are the locations at which the connecting members are joined to form a cylindrical structure (or said another way, the location at which the tubular inner frame 100 is cut to be opened up and flattened for the view shown in FIG. 4).


Another embodiment of an inner frame, in this instance designated 200, is shown in FIG. 5 in a flattened view. Inner frame 200 includes a cylindrical framework 202 defining a lumen 204. As in FIG. 4, this view in FIG. 5 is intended primarily for illustrative purposes of the wireframe structure, and point A and point B designate the locations at which the wireframe is joined to form a cylindrical structure.


Another embodiment of an inner frame, in this instance designated 300, is shown in flattened view in FIG. 6. Inner frame 300 includes three diamond-shaped members, not having spanning members. Cylindrical framework 302 defines a lumen 304 using each of diamond-shaped members 306, 308, and 310. FIG. 6 again shows point A and point B, which are the locations at which the connecting members are joined to form a cylindrical structure.


Another embodiment of an inner frame, in this instance designated 400, is shown in side view in FIG. 7. This four-diamond embodiment includes a cylindrical framework 402 defining a lumen 404, in which cylindrical framework 402 includes four generally diamond-shaped members.


A flattened view of another four-diamond embodiment of inner frame 400 is shown in a flattened view in FIG. 8. FIG. 8 shows diamond-shaped members 406, 407, 408, and 409, each having joining legs, shown for 406 as joining components (legs) 426 and 428, which define vertices, such as that shown at joined end 432. FIG. 8 also shows spanning members, such as that shown at 422, crossing the open span of the diamond-shaped members and providing a strengthening structural enhancement, another sewing anchor location, or both. FIG. 8 again shows point A and point B, which are the locations at which the connecting members are joined to form a cylindrical structure.


Another embodiment of an inner frame, in this instance designated 500, is shown in flattened view in FIG. 9. Inner frame 500 includes cylindrical framework 502 defining lumen 504.


Another embodiment of an inner frame, in this instance designated 600, is shown in flattened view in FIG. 10. Inner frame 600 includes cylindrical wireframe 602 defining a lumen 604 using diamond-shaped members 606, 607, 608, and 609. Each diamond-shaped member is joined at a connecting point, such as that shown at 628.


Another embodiment of an inner frame, in this instance designated 700, is shown in side view in FIG. 11 and in flattened view in FIG. 12. This embodiment has three square-shaped members connected by a v-shaped joining element. Square-shaped members 706, 708, and 710, each have a v-shaped joining element, such as that shown as 724. Inner frame 700 also includes lateral vertices 712, 714 and longitudinal vertices 716, 718 and spanning members, such as that shown at 722, crossing the open span of the square-shaped members and providing a strengthening structural enhancement, another sewing anchor location, or both. Again, point A and point B are the locations at which the integral connecting members make their connection to form a cylindrical structure.


Another embodiment of a prosthetic valve is shown in exploded view in FIG. 13. Valve 10′ also includes an inner structure or assembly 12 and an outer structure or assembly 14. Valve 10′ may also be coupled to a tether 160 and a tether anchor 154.


Inner assembly 12 includes inner frame 302, outer cylindrical wrap 152, and leaflet structure 136 (including articulating leaflets 138 that define a valve function). As in the embodiment in FIG. 1, leaflet structure 136 may be sewn to inner frame 302, and may use parts of inner frame 302 for this purpose. Inner assembly 12 is disposed within and secured within outer assembly 14.


Outer assembly 14 includes outer frame 144. Outer frame 144 may also have in various embodiments an outer frame cover of tissue or fabric (not pictured), or may be left without an outer cover to provide exposed wireframe to facilitate in-growth. Outer frame 144 has an articulating collar or cuff 147 is covered by cover 148 of tissue or fabric. Cuff 147 may also have in some embodiments a vertical A2 section to accommodate and solve left ventricular outflow tract (LVOT) obstruction issues.


In this embodiment, tether 160 is connected to valve 10′ by outer frame 144, in contrast to the embodiment in FIG. 1, in which the tether is attached to valve 10 by inner frame 100. To implement this alternative tether attachment, in this embodiment, outer frame 144 also has attachment members or struts 113. A tether anchor 156 can be attached to the lower ends of the struts, and tether 160 can be attached to tether anchor 156. In this embodiment, tether 160 can be connected to epicardial securing pad 154.


An embodiment of an outer frame 144 having attachment members or struts 113 is shown in FIGS. 14A to 14C. In this embodiment, outer frame 144 is formed from a milled or laser-cut tube of Nitinol®. FIG. 14A shows the tube as initially milled or laser cut, i.e. before deformation. The tube can be divided into four portions, corresponding to functionally different portions of the outer frame 144 in final form: cuff portion 246, frame body portion 245, strut portion 243, and tether connecting portion 242. Strut portion 243 includes six struts 213, which connect body portion 245 to tether clamp portion 242. Connecting portion 242 includes longitudinal extensions of struts 213, connected circumferentially by pairs of opposed, slightly V-shaped connecting members (or “micro-Vs”). Connecting portion 242 is configured to be radially collapsed by application of a compressive force, which causes the micro-Vs to become more deeply V-shaped, with the vertices moving closer together longitudinally and the open ends of the V shapes moving closer together circumferentially. In one embodiment, connecting portion 242 can be configured to compressively clamp or grip one end of a tether, either clamping directly onto a tether line (e.g. braided filament line) or onto an intermediate structure, such as a polymer or metal piece that is in term firmly fixed to the tether line. In another embodiment, connecting portion 242 can be coupled to a tether by a mechanical connection (e.g. stitches, pins, etc.), an adhesive connection, or any other suitable technique. In some embodiments, but clamping and one or more other connection techniques can be used in combination.


In contrast to connecting portion 242, cuff portion 246 and body portion 245 are configured to be expanded radially. Strut portion 243 forms a longitudinal connection, and radial transition, between the expanded body portion and the compressed connecting portion 242. FIG. 14B shows outer frame 244 in a partially deformed configuration, i.e. with connecting portion 242 compressed to a slightly smaller radial dimension than the initial configuration in FIG. 14A, and with cuff portion 246 and body portion 245 expanded to a slightly larger radial dimension. FIG. 14C shows outer frame 244 in a further partially deformed (though not fully deformed to the final, deployed configuration).


Another embodiment of a prosthetic valve is shown in exploded view in FIG. 15. Valve 10″ also includes an inner structure or assembly 312 and an outer structure or assembly 314. Valve 10″ may also be coupled to a tether 360 and a tether anchor 354.


Inner assembly 312 includes inner frame 340, outer cylindrical wrap 352, and leaflet structure 336 (including articulating leaflets 338 that define a valve function). As in the embodiment in FIGS. 1 and 13, leaflet structure 336 may be sewn to inner frame 340, and may use parts of inner frame 340 for this purpose. Inner assembly 312 is disposed within and secured within outer assembly 314, as described in more detail below.


Outer assembly 314 includes outer frame 370. Outer frame 370 may also have in various embodiments an outer frame cover of tissue or fabric (not pictured), or may be left without an outer cover to provide exposed wireframe to facilitate in-growth. Outer frame 370 may also have an articulating collar or cuff 347 covered by cover 348 of tissue or fabric.


In this embodiment, tether 360 is connected to valve 10″ by inner frame 340, similar to the embodiment in FIG. 1, but employing the connecting portion and strut portion features of the outer frame 144 of the valve 10′ in FIG. 13. Thus, inner frame 340 includes tether connecting or clamping portion 344 by which inner frame 340, and by extension valve 10″, is coupled to tether 360.


Inner frame 340 is shown in more detail in FIGS. 16-18. Inner frame 340 can be formed from a milled or laser-cut tube of, for example, Nitinol®. Inner frame 340 is illustrated in FIG. 16 in an undeformed, initial state, i.e. as milled or laser-cut, but cut and unrolled into a flat sheet for ease of illustration. Inner frame 340 can be divided into four portions, corresponding to functionally different portions of the inner frame 340 in final form: apex portion 341, body portion 342, strut portion 343, and tether clamp portion 344. Strut portion 343 includes six struts, such as strut 343A, which connect body portion 342 to tether clamp portion 344.


Connecting portion 344 includes longitudinal extensions of the struts, connected circumferentially by pairs of micro-V's. Similar to connecting portion 242 of outer frame 244 in FIGS. 14A-C, connecting portion 344 is configured to be radially collapsed by application of a compressive force, which causes the micro-Vs to become more deeply V-shaped, with the vertices moving closer together longitudinally and the open ends of the V shapes moving closer together circumferentially. Thus, connecting portion 344 can clamp or grip one end of a tether, either connecting directly onto a tether line (e.g. braided filament line) or onto an intermediate structure, such as a polymer or metal piece that is in term firmly fixed to the tether line. Other techniques can be used to connect a tether to connection portion 344, as discussed above for connection portion 242 of outer frame 244.


In contrast to connecting portion 344, apex portion 341 and body portion 342 are configured to be expanded radially. Strut portion 343 forms a longitudinal connection, and radial transition, between the expanded body portion and the compressed connecting portion 344.


Body portion 342 includes six longitudinal posts, such as post 342A. The posts can be used to attach leaflet structure 336 to inner frame 340, and/or can be used to attach inner assembly 312 to outer assembly 314, such as by connecting inner frame 340 to outer frame 370. In the illustrated embodiment, the posts include openings through which connecting members (such as suture filaments and/or wires) can be passed to couple the posts to other structures.


Inner frame 340 is shown in a fully deformed, i.e. to the final, deployed configuration, in side view and bottom view in FIGS. 17 and 18, respectively.


Outer frame 370 of valve 10″ is shown in more detail in FIGS. 19-21. Outer frame 370 can be formed from a milled or laser-cut tube of, for example, Nitinol®. Outer frame 370 is illustrated in FIG. 19 in an undeformed, initial state, i.e. as milled or laser-cut, but cut and unrolled into a flat sheet for ease of illustration. Outer frame 370 can be similar to outer frame 144 described above in connection with valves 10 and 10′. Outer frame 370 can be divided into a coupling portion 371, a body portion 372, and a cuff portion 373, as shown in FIG. 19.


Coupling portion 371 includes multiple openings or apertures, such as 371A, by which outer frame 370 can be coupled to inner frame 340, as discussed in more detail below.


In this embodiment, cuff portion 373 includes an indicator 374. In this embodiment, indicator 374 is simply a broader portion of the wire frame element of cuff portion 373, i.e. Indicator 374 is more apparent on radiographic or other imaging modalities than the surrounding wire frame elements of cuff portion 373. In other embodiments, indicator 374 can be any distinguishable feature (e.g., protrusion, notch, etc.) and/or indicia (e.g., lines, markings, tic marks, etc.) that enhance the visibility of the part of cuff portion 373 on which it is formed, or to which it is attached. Indicator 374 can facilitate the implantation of the prosthetic valve by providing a reference point or landmark that the operator can use to orient and/or position the valve (or any portion of the valve) with respect to the native valve or other heart structure. For example, during implantation, an operator can identify (e.g., using echocardiography) the indicator 373 when the valve is situated in a patient's heart. The operator can therefore determine the location and/or orientation of the valve and make adjustments accordingly.


Outer frame 370 is shown in a fully deformed, i.e. to the final, deployed configuration, in side view and top view in FIGS. 20 and 21, respectively. As best seen in FIG. 21, the lower end of coupling portion 371 forms a roughly circular opening (identified by “O” in FIG. 21). The diameter of this opening preferably corresponds approximately to the diameter of body portion 342 of inner frame 340, to facilitate coupling of the two components of valve 10″.


Outer frame 370 and inner frame 340 are shown coupled together in FIGS. 22-24, in front, side, and top views, respectively. The two frames collectively form a structural support for a prosthetic valve such as valve 10″ in FIG. 15. The frames support the valve leaflet structure in the desired relationship to the native valve annulus, support the coverings for the two frames to provide a barrier to blood leakage between the atrium and ventricle, and couple to the tether (by the inner frame 340) to aid in holding the prosthetic valve in place in the native valve annulus by the tether connection to the ventricle wall. The two frames are connected at six coupling points (representative points are identified as “C”). In this embodiment, the coupling points are implemented with a mechanical fastener, such as a short length of wire, passed through aperture (such as aperture 371A) in coupling portion 371 of outer frame 370 and corresponding openings in longitudinal posts (such as poste 342A) in body portion 342 of inner frame 340. Inner frame structure 340 is thus disposed within the outer frame 370 and secured coupled to it.


While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation, and as such, various changes in form and/or detail may be made. Any portion of the apparatus and/or methods described herein may be combined in any suitable combination, unless explicitly expressed otherwise. Where methods and/or schematics described above indicate certain events occurring in certain order, the ordering of certain events and/or flow patterns may be modified. Additionally, certain events may be performed concurrently in parallel processes when possible, as well as performed sequentially.

Claims
  • 1. A method of manufacturing a prosthetic heart valve, comprising: forming an outer frame of a shape memory alloy;forming an inner frame of a shape memory alloy, the inner frame having a first portion and a second portion;coupling the outer frame to the inner frame;coupling a prosthetic leaflet assembly to the first portion of the inner frame; andcompressing the second portion of the inner frame over a first end of a tether.
  • 2. The method of claim 1, wherein the shape memory alloy of the outer frame is a nickel-titanium alloy.
  • 3. The method of claim 1, wherein the shape memory alloy of the inner frame is a nickel-titanium alloy.
  • 4. The method of claim 1, wherein the outer frame is coupled to the inner frame by one or more mechanical fasteners.
  • 5. The method of claim 1, wherein the outer frame is formed separately from the inner frame.
  • 6. The method of claim 1, wherein after coupling the outer frame to the inner frame, a distal end of the outer frame is disposed distal to a distal end of the inner frame.
  • 7. The method of claim 1, wherein the inner frame is formed into an initial shape, and the first portion of the inner frame is expanded from the initial shape, wherein compressing the second portion of the inner frame includes compressing the second portion of the inner frame from the initial shape.
  • 8. The method of claim 7, wherein after compressing the second portion of the inner frame, the second portion of the inner frame defines a lumen having a width and a length that is greater than the width.
  • 9. The method of claim 1, wherein after compressing the second portion of the inner frame over the first end of the tether, the second portion of the inner frame is disposed circumferentially continuously around the first end of the tether.
  • 10. The method of claim 1, wherein the inner frame defines a central axis, and after compressing the second portion of the inner frame over the first end of the tether, the second portion of the inner frame is disposed along the central axis.
  • 11. The method of claim 1, wherein forming the inner frame includes forming the second portion of the inner frame to include a plurality of “V”-shaped strut members, and compressing the second portion of the inner frame includes causing vertices of adjacent “V’-shaped strut members to move closer together longitudinally, and causing open ends of individual ones of the “V” shaped strut members to move closer together circumferentially.
  • 12. The method of claim 1, wherein compressing the second portion of the inner frame over the first end of the tether includes compressing the second portion of the inner frame directly onto the first end of the tether.
  • 13. The method of claim 1, wherein compressing the second portion of the inner frame over the first end of the tether includes compressing the second portion of the inner frame onto an intermediate structure between the second portion of the inner frame and the first end of the tether.
  • 14. The method of claim 13, wherein the intermediate structure is a polymer or metal piece.
  • 15. The method of claim 1, further comprising additionally coupling the second portion of the inner frame to the first end of the tether by a mechanical connection.
  • 16. The method of claim 15, wherein the mechanical connection includes sutures.
  • 17. The method of claim 15, wherein the mechanical connection includes pins.
  • 18. The method of claim 1, further comprising additionally coupling the second portion of the inner frame to the first end of the tether by an adhesive.
  • 19. The method of claim 1, wherein the inner frame is formed from a tube of the shape memory alloy.
  • 20. The method of claim 1, wherein the outer frame is formed from a tube of the shape memory alloy.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/472,935, filed on Mar. 29, 2017, which is a continuation of U.S. patent application Ser. No. 14/950,656, filed Nov. 24, 2015 and issued as U.S. Pat. No. 9,610,159 on Apr. 4, 2017, which is a continuation of International Application No. PCT/US2014/040188, filed May 30, 2014, which claims priority to and is a continuation-in-part of U.S. patent application Ser. No. 14/155,417, filed Jan. 15, 2014, which claims priority to and the benefit of U.S. Provisional Application No. 61/829,076, filed May 30, 2013. International Application No. PCT/US2014/040188 also claims priority to and the benefit of U.S. Provisional Application No. 61/829,076, filed May 30, 2013. Each of the foregoing disclosures is hereby incorporated by reference in its entirety.

US Referenced Citations (776)
Number Name Date Kind
2697008 Ross Dec 1954 A
3409013 Berry Nov 1968 A
3472230 Fogarty et al. Oct 1969 A
3476101 Ross Nov 1969 A
3548417 Kischer Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3976079 Samuels et al. Aug 1976 A
4003382 Dyke Jan 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4073438 Meyer Feb 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4490859 Black et al. Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4585705 Broderick et al. Apr 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4626255 Reichart et al. Dec 1986 A
4638886 Marietta Jan 1987 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4824180 Levrai Apr 1989 A
4829990 Fhuroff et al. May 1989 A
4830117 Capasso May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4923013 De Gennaro May 1990 A
4960424 Grooters Oct 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
4996873 Takeuchi Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5035706 Giantureo et al. Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5201880 Wright et al. Apr 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5306296 Wright et al. Apr 1994 A
5332402 Teitelbaum Jul 1994 A
5336616 Livesey et al. Aug 1994 A
5344442 Deac Sep 1994 A
5360444 Kusuhara Nov 1994 A
5364407 Poll Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554184 Machiraju Sep 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5607462 Imran Mar 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5639274 Fischell et al. Jun 1997 A
5662704 Gross Sep 1997 A
5665115 Cragg Sep 1997 A
5674279 Wright et al. Oct 1997 A
5697905 d'Ambrosio Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5741333 Frid Apr 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5792179 Sideris Aug 1998 A
5800508 Goicoechea et al. Sep 1998 A
5833673 Ockuly et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5904697 Gifford, III et al. May 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968052 Sullivan, III et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5972030 Garrison et al. Oct 1999 A
5993481 Marcade et al. Nov 1999 A
6027525 Suh et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6045497 Schweich, Jr. et al. Apr 2000 A
6063112 Sgro May 2000 A
6077214 Mortier et al. Jun 2000 A
6099508 Bousquet Aug 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6183411 Mortier et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6260552 Mortier et al. Jul 2001 B1
6261222 Schweich, Jr. et al. Jul 2001 B1
6264602 Mortier et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6350277 Kocur Feb 2002 B1
6358277 Duran Mar 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6402679 Mortier et al. Jun 2002 B1
6402680 Mortier et al. Jun 2002 B2
6402781 Langberg et al. Jun 2002 B1
6406420 McCarthy et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6537198 Vidlund et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6569196 Vesely May 2003 B1
6575252 Reed Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6605112 Moll et al. Aug 2003 B1
6616684 Vidlund et al. Sep 2003 B1
6622730 Ekvall et al. Sep 2003 B2
6629534 Goar et al. Oct 2003 B1
6629921 Schweich, Jr. et al. Oct 2003 B1
6648077 Hoffman Nov 2003 B2
6648921 Anderson et al. Nov 2003 B2
6652578 Bailey et al. Nov 2003 B2
6669724 Park et al. Dec 2003 B2
6706065 Langberg et al. Mar 2004 B2
6709456 Langberg et al. Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6740105 Yodfat et al. May 2004 B2
6746401 Panescu Jun 2004 B2
6746471 Mortier et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6810882 Langberg et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6854668 Wancho et al. Feb 2005 B2
6855144 Lesh Feb 2005 B2
6858001 Aboul-Hosn Feb 2005 B1
6890353 Cohn et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908424 Mortier et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6936067 Buchanan Aug 2005 B2
6945996 Sedransk Sep 2005 B2
6955175 Stevens et al. Oct 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976543 Fischer Dec 2005 B1
6997950 Chawla Feb 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7044905 Vidlund et al. May 2006 B2
7060021 Wilk Jun 2006 B1
7077862 Vidlund et al. Jul 2006 B2
7087064 Hyde Aug 2006 B1
7100614 Stevens et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7108717 Freidberg Sep 2006 B2
7112219 Vidlund et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7141064 Scott et al. Nov 2006 B2
7175656 Khairkhahan Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7247134 Vidlund et al. Jul 2007 B2
7252682 Seguin Aug 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7275604 Wall Oct 2007 B1
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7316706 Bloom et al. Jan 2008 B2
7318278 Zhang et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329278 Seguin et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7374571 Pease et al. May 2008 B2
7377941 Rhee et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7404824 Webler et al. Jul 2008 B1
7416554 Lam et al. Aug 2008 B2
7422072 Dade Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7500989 Solem et al. Mar 2009 B2
7503931 Kowalsky et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513908 Lattouf Apr 2009 B2
7524330 Berreklouw Apr 2009 B2
7527647 Spence May 2009 B2
7534260 Lattouf May 2009 B2
7556646 Yang et al. Jul 2009 B2
7579381 Dove Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591847 Navia et al. Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7632304 Park Dec 2009 B2
7632308 Loulmet Dec 2009 B2
7635386 Gammie Dec 2009 B1
7674222 Nikolic et al. Mar 2010 B2
7674286 Alfieri et al. Mar 2010 B2
7695510 Bloom et al. Apr 2010 B2
7708775 Rowe et al. May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7766961 Patel et al. Aug 2010 B2
7789909 Andersen et al. Sep 2010 B2
7803168 Gifford et al. Sep 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7806928 Rowe et al. Oct 2010 B2
7837727 Goetz et al. Nov 2010 B2
7854762 Speziali et al. Dec 2010 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7901454 Kapadia et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7931630 Nishtala et al. Apr 2011 B2
7942928 Webler et al. May 2011 B2
7955247 Levine et al. Jun 2011 B2
7955385 Crittenden Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7988727 Santamore et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8007992 Tian et al. Aug 2011 B2
8029556 Rowe Oct 2011 B2
8043368 Crabtree Oct 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8052751 Aklog et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8109996 Stacchino et al. Feb 2012 B2
8142495 Hasenkam et al. Mar 2012 B2
8152821 Gambale et al. Apr 2012 B2
8157810 Case et al. Apr 2012 B2
8167932 Bourang et al. May 2012 B2
8167934 Styrc et al. May 2012 B2
8187299 Goldfarb et al. May 2012 B2
8206439 Gomez Duran Jun 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8226711 Mortier et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8241274 Keogh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308796 Lashinski et al. Nov 2012 B2
8323334 Deem et al. Dec 2012 B2
8353955 Styrc et al. Jan 2013 B2
RE44075 Williamson et al. Mar 2013 E
8449599 Chau et al. May 2013 B2
8454656 Tuval Jun 2013 B2
8470028 Thornton et al. Jun 2013 B2
8480730 Maurer et al. Jul 2013 B2
8486138 Vesely Jul 2013 B2
8506623 Wilson et al. Aug 2013 B2
8506624 Vidlund et al. Aug 2013 B2
8578705 Sindano et al. Nov 2013 B2
8579913 Nielsen Nov 2013 B2
8591573 Barone Nov 2013 B2
8591576 Hasenkam et al. Nov 2013 B2
8597347 Maurer et al. Dec 2013 B2
8685086 Navia et al. Apr 2014 B2
8790394 Miller et al. Jul 2014 B2
8845717 Khairkhahan et al. Sep 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8900214 Nance et al. Dec 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8926696 Cabiri et al. Jan 2015 B2
8932342 McHugo et al. Jan 2015 B2
8932348 Solem et al. Jan 2015 B2
8945208 Jimenez et al. Feb 2015 B2
8956407 Macoviak et al. Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986376 Solem Mar 2015 B2
9011522 Annest Apr 2015 B2
9023099 Duffy et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9039759 Alkhatib et al. May 2015 B2
9078645 Conklin et al. Jul 2015 B2
9078749 Lutter et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095433 Lutter et al. Aug 2015 B2
9125742 Yoganathan et al. Sep 2015 B2
9149357 Seguin Oct 2015 B2
9161837 Kapadia Oct 2015 B2
9168137 Subramanian et al. Oct 2015 B2
9232995 Kovalsky et al. Jan 2016 B2
9232998 Wilson et al. Jan 2016 B2
9232999 Maurer et al. Jan 2016 B2
9241702 Maisano et al. Jan 2016 B2
9254192 Lutter et al. Feb 2016 B2
9265608 Miller et al. Feb 2016 B2
9289295 Aklog et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9345573 Nyuli et al. May 2016 B2
9480557 Pellegrini et al. Nov 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9526611 Tegels et al. Dec 2016 B2
9597181 Christianson et al. Mar 2017 B2
9610159 Christianson Apr 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9730792 Lutter et al. Aug 2017 B2
9827092 Vidlund et al. Nov 2017 B2
9833315 Vidlund et al. Dec 2017 B2
9867700 Bakis et al. Jan 2018 B2
9883941 Hastings et al. Feb 2018 B2
9895221 Vidlund Feb 2018 B2
9986993 Vidlund et al. Jun 2018 B2
20010018611 Solem et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025171 Mortier et al. Sep 2001 A1
20020010427 Scarfone et al. Jan 2002 A1
20020116054 Lundell et al. Aug 2002 A1
20020139056 Finnell Oct 2002 A1
20020151961 Lashinski et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020173842 Buchanan Nov 2002 A1
20020183827 Derus et al. Dec 2002 A1
20030010509 Hoffman Jan 2003 A1
20030036698 Kohler et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030078652 Sutherland Apr 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030105520 Alferness et al. Jun 2003 A1
20030120340 Liska et al. Jun 2003 A1
20030130731 Vidlund et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040039436 Spenser et al. Feb 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040055606 Hendricksen et al. Mar 2004 A1
20040064014 Melvin et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040097865 Anderson et al. May 2004 A1
20040127983 Mortier et al. Jul 2004 A1
20040133263 Dusbabek et al. Jul 2004 A1
20040147958 Lam et al. Jul 2004 A1
20040152947 Schroeder et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040163828 Silverstein et al. Aug 2004 A1
20040181239 Dorn et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20050004652 van der Burg et al. Jan 2005 A1
20050004666 Alfieri et al. Jan 2005 A1
20050075727 Wheatley Apr 2005 A1
20050080402 Santamore et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096498 Houser et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050107661 Lau et al. May 2005 A1
20050113798 Slater et al. May 2005 A1
20050113810 Houser et al. May 2005 A1
20050113811 Houser et al. May 2005 A1
20050119519 Girard et al. Jun 2005 A9
20050121206 Dolan Jun 2005 A1
20050125012 Houser et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050148815 Mortier et al. Jul 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050256567 Lim et al. Nov 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060042803 Gallaher Mar 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060052868 Mortier et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060094983 Burbank et al. May 2006 A1
20060129025 Levine et al. Jun 2006 A1
20060142784 Kontos Jun 2006 A1
20060161040 McCarthy et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060247491 Vidlund et al. Nov 2006 A1
20060252984 Rahdert et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20060287716 Banbury et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070005231 Seguchi Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070038291 Case et al. Feb 2007 A1
20070050020 Spence Mar 2007 A1
20070061010 Hauser et al. Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070073387 Forster et al. Mar 2007 A1
20070078297 Rafiee et al. Apr 2007 A1
20070083076 Lichtenstein Apr 2007 A1
20070083259 Bloom et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070112425 Schaller et al. May 2007 A1
20070118151 Davidson May 2007 A1
20070118154 Crabtree May 2007 A1
20070118210 Pinchuk May 2007 A1
20070118213 Loulmet May 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070162048 Quinn et al. Jul 2007 A1
20070162103 Case et al. Jul 2007 A1
20070168024 Khairkhahan Jul 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070185571 Kapadia et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070215362 Rodgers Sep 2007 A1
20070221388 Johnson Sep 2007 A1
20070233239 Navia et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070256843 Pahila Nov 2007 A1
20070265658 Nelson et al. Nov 2007 A1
20070267202 Mariller Nov 2007 A1
20070270932 Headley et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20070293944 Spenser et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082163 Woo Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080091264 Machold et al. Apr 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125861 Webler et al. May 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183203 Fitzgerald et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080243150 Starksen et al. Oct 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080288060 Kaye et al. Nov 2008 A1
20080293996 Evans et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090048668 Wilson et al. Feb 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054974 McGuckin, Jr. et al. Feb 2009 A1
20090062908 Bonhoeffer et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090082619 De Marchena Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099410 De Marchena Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090131849 Maurer et al. May 2009 A1
20090132035 Roth et al. May 2009 A1
20090137861 Goldberg et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090164005 Dove et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090177266 Powell et al. Jul 2009 A1
20090192601 Rafiee et al. Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090224529 Gill Sep 2009 A1
20090234318 Loulmet et al. Sep 2009 A1
20090234435 Johnson et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248149 Gabbay Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090292262 Adams et al. Nov 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090326575 Galdonik et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100021382 Dorshow et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100161041 Maisano et al. Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100179641 Ryan et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100185278 Schankereli Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100192402 Yamaguchi et al. Aug 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100210899 Schankereli Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249489 Jarvik Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100280604 Zipory et al. Nov 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298755 McNamara et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110015616 Straubinger et al. Jan 2011 A1
20110015728 Jimenez et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110029072 Gabbay Feb 2011 A1
20110054519 Neuss Mar 2011 A1
20110066231 Cartledge et al. Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110112632 Chau et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137408 Bergheim Jun 2011 A1
20110224655 Asirvatham et al. Sep 2011 A1
20110224678 Gabbay Sep 2011 A1
20110224728 Martin et al. Sep 2011 A1
20110224784 Quinn Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110288637 De Marchena Nov 2011 A1
20110301703 Glazier Dec 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120016468 Robin et al. Jan 2012 A1
20120021530 Gellman Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120053686 McNamara et al. Mar 2012 A1
20120059487 Cunanan et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120089171 Hastings et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120116351 Chomas et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120158129 Duffy et al. Jun 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120203336 Annest Aug 2012 A1
20120215303 Quadri Aug 2012 A1
20120226348 Lane et al. Sep 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120289945 Segermark Nov 2012 A1
20130030522 Rowe et al. Jan 2013 A1
20130053950 Rowe et al. Feb 2013 A1
20130066341 Ketai et al. Mar 2013 A1
20130079873 Migliazza et al. Mar 2013 A1
20130131788 Quadri et al. May 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130184811 Rowe et al. Jul 2013 A1
20130190860 Sundt, III Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130226288 Goldwasser et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130274874 Hammer Oct 2013 A1
20130282101 Eidenschink et al. Oct 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130317603 McLean et al. Nov 2013 A1
20130325041 Annest et al. Dec 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20130338752 Geusen et al. Dec 2013 A1
20140046433 Kovalsky Feb 2014 A1
20140081323 Hawkins Mar 2014 A1
20140094918 Vishnubholta et al. Apr 2014 A1
20140142691 Pouletty May 2014 A1
20140163668 Rafiee Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140243966 Garde et al. Aug 2014 A1
20140277419 Garde et al. Sep 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140296970 Ekvall et al. Oct 2014 A1
20140296971 Tegels et al. Oct 2014 A1
20140296972 Tegels et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303718 Tegels et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316516 Vidlund et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324161 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140331475 Duffy et al. Nov 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140364942 Straubinger et al. Dec 2014 A1
20140364944 Lutter et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150005874 Vidlund et al. Jan 2015 A1
20150011821 Gorman et al. Jan 2015 A1
20150025553 Del Nido et al. Jan 2015 A1
20150057705 Vidlund Feb 2015 A1
20150073542 Heldman Mar 2015 A1
20150073545 Braido Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150105856 Rowe et al. Apr 2015 A1
20150119936 Gilmore et al. Apr 2015 A1
20150119978 Tegels et al. Apr 2015 A1
20150127093 Hosmer et al. May 2015 A1
20150127096 Rowe et al. May 2015 A1
20150134050 Solem et al. May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150142101 Coleman et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150142104 Braido May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150196688 James Jul 2015 A1
20150202044 Chau et al. Jul 2015 A1
20150216653 Freudenthal Aug 2015 A1
20150216660 Pintor Aug 2015 A1
20150223820 Olson Aug 2015 A1
20150223934 Vidlund et al. Aug 2015 A1
20150238312 Lashinski Aug 2015 A1
20150238729 Jenson et al. Aug 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150305860 Wang et al. Oct 2015 A1
20150305864 Quadri et al. Oct 2015 A1
20150305868 Lutter et al. Oct 2015 A1
20150327995 Morin et al. Nov 2015 A1
20150328001 McLean Nov 2015 A1
20150335424 McLean Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150342717 O'Donnell et al. Dec 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20160000562 Siegel Jan 2016 A1
20160008131 Christianson et al. Jan 2016 A1
20160067042 Murad et al. Mar 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106537 Christianson et al. Apr 2016 A1
20160113764 Sheahan Apr 2016 A1
20160143736 Vidlund May 2016 A1
20160151155 Lutter et al. Jun 2016 A1
20160206280 Vidlund et al. Jul 2016 A1
20160242902 Morriss Aug 2016 A1
20160262879 Meiri et al. Sep 2016 A1
20160262881 Schankereli et al. Sep 2016 A1
20160278955 Liu et al. Sep 2016 A1
20160317290 Chau Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160346086 Solem Dec 2016 A1
20160367365 Conklin Dec 2016 A1
20160367367 Maisano et al. Dec 2016 A1
20160367368 Vidlund et al. Dec 2016 A1
20170079790 Vidlund et al. Mar 2017 A1
20170100248 Tegels et al. Apr 2017 A1
20170128208 Christianson et al. May 2017 A1
20170181854 Christianson et al. Jun 2017 A1
20170252153 Chau et al. Sep 2017 A1
20170266001 Vidlund et al. Sep 2017 A1
20170281343 Christianson et al. Oct 2017 A1
20170312076 Lutter et al. Nov 2017 A1
20170312077 Vidlund et al. Nov 2017 A1
20170319333 Tegels et al. Nov 2017 A1
20180028314 Ekvall et al. Feb 2018 A1
20180078368 Vidlund et al. Mar 2018 A1
20180078370 Kovalsky et al. Mar 2018 A1
20180147055 Vidlund et al. May 2018 A1
20180193138 Vidlund Jul 2018 A1
20180263618 Vidlund et al. Sep 2018 A1
Foreign Referenced Citations (145)
Number Date Country
1486161 Mar 2004 CN
1961845 May 2007 CN
2902226 May 2007 CN
101146484 Mar 2008 CN
101180010 May 2008 CN
101180010 Dec 2010 CN
101984938 Mar 2011 CN
102639179 Aug 2012 CN
102869317 Jan 2013 CN
102869318 Jan 2013 CN
102869321 Jan 2013 CN
103220993 Jul 2013 CN
102639179 Oct 2014 CN
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049815 Apr 2002 DE
102006052564 Dec 2007 DE
102006052710 May 2008 DE
102007043830 Apr 2009 DE
102007043831 Apr 2009 DE
0103546 Mar 1984 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1469797 Oct 2004 EP
1469797 Nov 2005 EP
2111800 Oct 2009 EP
2193762 Jun 2010 EP
2278944 Feb 2011 EP
2747707 Jul 2014 EP
2918248 Sep 2015 EP
2788217 Jul 2000 FR
2815844 May 2002 FR
2003505146 Feb 2003 JP
2005515836 Jun 2005 JP
2007509700 Apr 2007 JP
2008541863 Nov 2008 JP
2009514628 Apr 2009 JP
2009519783 May 2009 JP
2012504031 Feb 2012 JP
2012518465 Aug 2012 JP
2012519024 Aug 2012 JP
2013512765 Apr 2013 JP
1017275 Aug 2002 NL
1271508 Nov 1986 SU
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9829057 Jul 1998 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
2000018333 Apr 2000 WO
2000030550 Jun 2000 WO
200041652 Jul 2000 WO
200047139 Aug 2000 WO
2001035878 May 2001 WO
2001049213 Jul 2001 WO
2001054624 Aug 2001 WO
2001054625 Aug 2001 WO
2001056512 Aug 2001 WO
2001061289 Aug 2001 WO
0176510 Oct 2001 WO
200176510 Oct 2001 WO
0182840 Nov 2001 WO
2001082840 Nov 2001 WO
2002004757 Jan 2002 WO
0222054 Mar 2002 WO
2002022054 Mar 2002 WO
2002028321 Apr 2002 WO
0236048 May 2002 WO
2002036048 May 2002 WO
2002041789 May 2002 WO
0243620 Jun 2002 WO
0249540 Jun 2002 WO
2002043620 Jun 2002 WO
2002049540 Jun 2002 WO
2002076348 Oct 2002 WO
2003003943 Jan 2003 WO
2003030776 Apr 2003 WO
2003047468 Jun 2003 WO
2003049619 Jun 2003 WO
2004019825 Mar 2004 WO
2005102181 Nov 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006064490 Jun 2006 WO
2006070372 Jul 2006 WO
2006105009 Oct 2006 WO
2006113906 Oct 2006 WO
2006127756 Nov 2006 WO
2007081412 Jul 2007 WO
2007100408 Sep 2007 WO
2008005405 Jan 2008 WO
2008035337 Mar 2008 WO
2008091515 Jul 2008 WO
2008125906 Oct 2008 WO
2008147964 Dec 2008 WO
2009024859 Feb 2009 WO
2009026563 Feb 2009 WO
2009045338 Apr 2009 WO
2009132187 Oct 2009 WO
2010090878 Aug 2010 WO
2010098857 Sep 2010 WO
2010121076 Oct 2010 WO
2011017440 Feb 2011 WO
2011022658 Feb 2011 WO
2011069048 Jun 2011 WO
2011072084 Jun 2011 WO
2011106735 Sep 2011 WO
2011109813 Sep 2011 WO
2011159342 Dec 2011 WO
2011163275 Dec 2011 WO
2012027487 Mar 2012 WO
2012036742 Mar 2012 WO
2012095116 Jul 2012 WO
2012177942 Dec 2012 WO
2013028387 Feb 2013 WO
2013045262 Apr 2013 WO
2013059747 Apr 2013 WO
2013028387 May 2013 WO
2013096411 Jun 2013 WO
2013175468 Nov 2013 WO
2014121280 Aug 2014 WO
2014144937 Sep 2014 WO
2014162306 Oct 2014 WO
2014189974 Nov 2014 WO
2015051430 Apr 2015 WO
2015058039 Apr 2015 WO
2015063580 May 2015 WO
2015065646 May 2015 WO
2015120122 Aug 2015 WO
2015138306 Sep 2015 WO
2015173609 Nov 2015 WO
2016112085 Jul 2016 WO
2016126942 Aug 2016 WO
2016168609 Oct 2016 WO
2016196933 Dec 2016 WO
2017096157 Jun 2017 WO
2017132008 Aug 2017 WO
2017218375 Dec 2017 WO
2018005779 Jan 2018 WO
2018013515 Jan 2018 WO
Non-Patent Literature Citations (67)
Entry
US 9,155,620 B2, 10/2015, Gross et al. (withdrawn)
Japanese Office Action for Application No. 2020105100, dated Jun. 4, 2021, 4 pages.
A. P. Yoganathan et al., “The Current Status of Prosthetic Heart Valves, Polymetric Materials and Artificial Organs,” American Chemical Society , Mar. 20, 1983 pp. 111-150.
Bernacca, G. M. et al., “Polyurethane heart valves: Fatigue failure, calcification, and polyurethane structure,” Journal of Biomedical Materials Research, Mar. 5, 1997, 34(3):371-379.
Buckberg, G. et al., “Restoring Papillary Muscle Dimensions During Restoration in Dilated Hearts,” Interactive Cardiovascular and Thoracic Surgery, 2005, 4:475-477.
Drawbaugh, K., “Feature—Heart Surgeons Explore Minimally Invasive Methods,” Reuters Limited, Jul. 16, 1996, 3 pages.
Henning Rud Andersen, “Transluminal Catheter Implanted Prosthetic Heart Valves,” International Journal of Angiology, 1998, Issue 2, vol. 7 pp. 102-106.
Moazami, N. et al., “Transluminal aortic valve placement: A feasibility study with a newly designed collapsible aortic valve,” ASAIO Journal, Sep./Oct. 1996 42(5):M381-M385.
Rousseau, E. P. M. et al., “A mechanical analysis of the closed Hancock heart valve prosthesis,” Journal of Biomechanics, 1988, 21(7):545-562.
Uchida, B. T. et al., “Modifications of Gianturco Expandable Wire Stents,” Am. J. Roentgenol., May 1988, 150 (5):1185-1187.
US 9,155,620, 10/2015, Gross et al. (withdrawn)
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Sigwart, U., “An Overview of Intravascular Stents: Old and New,” Chapter 48, Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Third Office Action for Chinese Application No. 201480037269.5, dated Jun. 19, 2018, 8 pages.
Tofeig, M. et al., “Transcatheter Closure of a Mid-Muscular Ventricular Septal Defect with an Amplatzer VSD Occluder Device,” Heart, 1999, 81:438-440.
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, pp. 227-230.
Webb, J. G. et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation, 2006, 113:842-850.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, ButtenNorths 1986.
Yoganathan, A. P. et al., “The Current Status of Prosthetic Heart Valves,” In Polymetric Materials and Artificial Organs, Mar. 20, 1983, pp. 111-150, American Chemical Society.
“Shape Memory Alloys,” Retrieved from the Internet: <http://webdocs.cs.ualberta.ca/˜database/MEMS/sma.html>, Feb. 5, 2016, 3 pages.
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenos's,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Al-Khaja, N. et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, Jun. 30, 1989, 3:305-311.
Almagor, Y. et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, Nov. 1, 1990, 16(6):1310-1314.
Andersen, H. R., “History of Percutaneous Aortic Valve Prosthesis,” Herz, Aug. 2009, 34(5):343-346.
Andersen, H. R., “Transluminal catheter implanted prosthetic heart valves,” International Journal of Angiology, 1998, 7(2):102-106.
Benchimol, A. et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977, 273(1):55-62.
Boudjemline, Y. et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves: An Experimental Study,” Journal of the American College of Cardiology, Jul. 2005, 46(2):360-365.
Chamberlain, G., “Ceramics Replace Body Parts,” Design News, Jun. 9, 1997, Issue 11, vol. 52, 5 pages.
Choo, S. J. et al., “Aortic Root Geometry: Pattern of Differences Between Leaflets and Sinuses of Valsava,” The Journal of Heart Valve Disease, Jul. 1999, 8:407-415.
Declaration of Malcolm J. R. Dalrymple-Hay, Nov. 9, 2012, pp. 1-11; with Curriculum Vitae, Oct. 4, 2012.
Dotter, C. T. et al., “Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of its Application,” Circulation, Nov. 1964, 30:654-670.
Examination Report for European Application No. 14734333.9, dated Oct. 20, 2016, 6 pages.
Examination Report No. 1 for Australian Application No. 2014274056, dated Mar. 6, 2018, 4 pages.
Examination Report No. 2 for Australian Application No. 2014274056, dated May 9, 2018, 2 pages.
Extended European Search Report for European Application No. 18160595.7, dated Sep. 14, 2018, 7 pages.
G. M. Bernacca, et al., “Polyurethane Heart Valves: Fatigue Failure, Calcification, and Polyurethane Structure,” Journal of Biomedical Materials Research, Mar. 5, 1997, Issue 3, vol. 34, pp. 371-379.
Gray, H., The Aorta, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://www.bartleby.com/107/142.html>, Dec. 10, 2012, 5 pages.
Gray, H., The Heart, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://education.yahoo.com/reference/gray/subjects/subject/138>, Aug. 10, 2012, 9 pages.
Greenhalgh, E. S., “Design and characterization of a biomimetic prosthetic aortic heart valve,” 1994, ProQuest Dissertations and Theses, Department of Fiber and Polymer Science, North Carolina State University at Raleigh, 159 pages.
H. R. Andersen et al., “Transluminal Implantation of Artificial Heart Valves: Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs,” European Heart Journal, 1992, Issue 5, vol. 13, pp. 704-708.
Inoue, K. et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery, 1984, 87:394-402.
International Search Report and Written Opinion for International Application No. PCT/US2014/040188, dated Nov. 17, 2014, 12 pages.
Invitation to Pay Additional Fees and Partial International Search Report for International Application No. PCT/US2014/040188, dated Sep. 8, 2014, 5 pages.
Jin, X. Y. et al., “Aortic Root Geometry and Stentless Porcine Valve Competence,” Seminars in Thoracic and Cardiovascular Surgery, Oct. 1999, 11(4):145-150.
Kolata, G., “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” New York Times [online], <http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-ar-teries-gets-a-faili . . . ,>, published Jan. 3, 1991,retrieved from the Internet on Feb. 5, 2016, 3 pages.
L. L. Knudsen et al., “Catheter-Implanted Prosthetic Heart Valves. Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs,” International Journal of Artificial Organs, 1993, Issue 5, vol. 16, pp. 253-262.
Lawrence, D. D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 1987, 163:357-360.
Lozonschi, L., et al. “Transapical mitral valved stent implantation: A survival series in swine,” The Journal of Thoracic and Cardiovascular Surgery, 140(2):422-426 (Aug. 2010) published online Mar. 12, 2010, 1 page.
Lutter, Georg, et al., Mitral valved stent implantation, European Journal of Cardio-Thoracic Surgery, 2010, vol. 38, pp. 350-355.
Ma, L. et al., “Double-crowned valved stents for off-pump mitral valve replacement,” European Journal of Cardio-Thoracic Surgery, Aug. 2005, 28(2): 194-198.
Notice of Reasons for Rejection for Japanese Application No. 2016-517032, dated Feb. 13, 2018, 5 pages.
Office Action for Chinese Application No. 201480037269.5, dated Dec. 23, 2016.
Office Action for U.S. Appl. No. 14/950,656, dated Apr. 22, 2016, 5 pages.
Orton, C., “Mitralseal: Hybrid Transcatheter Mitral Valve Replacement,” Symposium: Small Animal Proceedings, 2011, pp. 311-312.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Porstmann, W. et al., “Der Verschluβ des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, Apr. 1967, pp. 199-203.
Rashkind, W. J., “Creation of an Atrial Septal Defect Without Thoracotomy,” The Journal of the American Medical Association, Jun. 13, 1966, 196( 11 ): 173-174.
Rashkind, W. J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Dec. 1986, 13(4):363-367.
Reul, H. et al., “The Geomety of the Aortic Root in Health, at Valve Disease and After Valve Replacement,” J. Biomechanics, 1990, 23(2):181-191.
Robert C. Ashton Jr., “Development of an Intraluminal Device for the Treatment of Aortic Regurgitation: Prototype and in Vitro Testing System,” Journal of Thoracic and Cardiovascular Surgery, 1996, Issue/vol. 112, pp. 979-983.
Rosch, J. et al., “The Birth, Early Years and Future of Interventional Radiology,” J Vase Interv Radiol., Jul. 2003, 4:841-853.
Ross, D. N., “Aortic Valve Surgery,” Guys Hospital, London, 1968, pp. 192-197.
Rousseau, E. P. M. et al., “A Mechanical Analysis of the Closed Hancock Heart Valve Prosthesis,” Journal of Biomechanics, 1998, 21(7):545-562.
Sabbah, A. N. et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Dec. 1989, Journal of Cardiac Surgery, 4(4):302-309.
Second Office Action for Chinese Application No. 201480037269.5, dated Nov. 6, 2017, 6 pages.
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538.
Related Publications (1)
Number Date Country
20190336282 A1 Nov 2019 US
Provisional Applications (1)
Number Date Country
61829076 May 2013 US
Continuations (3)
Number Date Country
Parent 15472935 Mar 2017 US
Child 16513911 US
Parent 14950656 Nov 2015 US
Child 15472935 US
Parent PCT/US2014/040188 May 2014 US
Child 14950656 US
Continuation in Parts (1)
Number Date Country
Parent 14155417 Jan 2014 US
Child PCT/US2014/040188 US